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medical costs (2014 purchases and price tabulators) where retrieved to adopt the 
national health system perspective. Information gaps related to the use and fre-
quency of medical resources where fulfilled with the results of a Delphi panel (10 
oncologists of all major public institutions). The model was populated with the 
results of a Network Meta-Analysis. Both probabilistic and deterministic sensitiv-
ity analysis were performed to back up the results. RESULTS: Life years in PFS and 
OS gave an advantage to afatinib with 1.17 and 2.21 years respectively, followed by 
erlotinib with 1.11 and 2.07, gefitnib with 1.02 and 2.12 and pemetrexed/cisplatin 
with 0.63 and 2.07. Least costly therapy was afatinib with total treatment costs 
until death of US$100,152, followed by erlotinib, gefitinib and pemetrexed/cisplatin 
with 141,040 USD, 141,176 USD and 175,889 USD respectively. Afatinib, erlotinib 
and gefitinib resulted dominant therapies against pemetrexed/cisplatin. A further 
analysis showed a dominance of afatinib versus the others TKIs. Results were robust 
to changes in the time horizon (1 to 5 years) and prices (±10%). CONCLUSIONS: 
Afatinib resulted to be a cost-saving therapy against all comparators, presenting 
the least costly treatment and the most life years gained in terms of both PFS and 
OS from a Mexican public health perspective.
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OBJECTIVES: To establish the incremental cost-effectiveness ratio (ICER) of tyrosine-
kinase inhibitors (TKIs) afatinib, erlotinib and gefitinib versus pemetrexed/cisplatin 
in presence of EGFR mutations from a public Mexican perspective. Main efficacy 
endpoint was progression free survival (PFS) and secondary endpoint overall sur-
vival (OS). METHODS: A discrete event simulation CE model was developed to 
assess PFS, OS and treatment related costs until death in a five year time hori-
zon. Three relevant clinical health outcomes were assessed in one month length 
cycles: Progression free, disease progression and death. Public institutional direct 
